Rusfertide is a novel therapeutic option for patients with ET. Many patients with ET are phlebotomy dependent to reduce of thrombosis risk. Rusfertide is exciting because it is a hepcidin memetic that can lower the hematocrit without effects on other blood counts and without causing iron deficiency. #ASCO22 #MPNs
Read the full article here
Elizabeth A Moore, BSN, RN, MBA, and colleagues from University of Iowa Health Care discuss how their design and clinical teams overcame challenges to achieve…
A man in his 40s was referred for an 8-mm red, firm, mobile nodule with irregular red lacunae and vessels and an absence of septa.…
Join us at PFCCS – May 2024 Mon May 13, 2024 for another great experience.
About 11% of US children aged 5 to 17 years have been diagnosed with attention-deficit/hyperactivity disorder (ADHD), based on data from the National Health Interview…
A proteogenomic analysis found savolitinib plus osimertinib elicited a response in patients with EGFR-mutated, MET-amplified advanced NSCLC.
Introduction Systemic lupus erythematosus with antiphospholipid syndrome (SLE-APS) represents a challenging SLE endotype whose molecular basis remains unknown. Methods We analysed whole-blood RNA-sequencing data from…
Nineteen people from nine states have reported harmful reactions after receiving cosmetic injections — commonly known as “botox” — that were administered from unlicensed or…
Pests tackled by York and Scarborough Teaching Hospitals Trust include rats and cockroaches.
Two visitors at Lake Mead National Recreation Area were captured on video destroying ancient rock formations and park rangers are seeking the public’s help in…
